Changing from Mounjaro to Wegovy: what the reviews and evidence say

What do people actually experience when they make this switch?

Online reviews of switching from Mounjaro to Wegovy tend to cluster around a few consistent themes. Some people report that appetite suppression feels noticeably less potent on semaglutide after being on tirzepatide, while others describe the gastrointestinal side-effect profile as easier to tolerate. Neither pattern is universal. What reviews almost never capture is the clinical context behind each individual switch: a change in circumstances, a prescriber's recommendation, or a supply issue rather than a preference.

There is a common misconception worth gently setting aside here: that switching medicines mid-treatment means starting over from zero. Clinically, that's not quite right. The underlying biology has shifted during treatment, and many people continue to see progress on a different agent, particularly if they move with appropriate clinical support. The accounts from people who have swapped from Mounjaro to Wegovy suggest the transition tends to be smoother when managed by a prescriber rather than done abruptly.

A prescriber's view of your progress, your current dose, and any comorbidities matters more than any review thread. Our clinical team, led by a GPhC-registered prescriber, reviews every case individually before a switch is approved.

What does the clinical evidence say about the two medicines' effectiveness?

Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both supported by substantial trial evidence, but they differ in mechanism and, on average, in magnitude of effect. Tirzepatide activates both GIP and GLP-1 receptors; semaglutide targets only the GLP-1 pathway. That dual action appears to translate to greater average weight loss in direct comparison.

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, was the first large head-to-head study: tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes. SURMOUNT-1 had already shown around 20–21% average body-weight reduction at 15mg tirzepatide across thousands of trial participants, as NICE's appraisal of tirzepatide (TA1026) discusses. Semaglutide 2.4mg produced around 15% average reduction in STEP 1.

That said, the newer 7.2mg Wegovy dose (approved by the MHRA in January 2026 and available as a single-dose pen from April 2026) narrows the gap considerably, with around 20.7% average loss reported over 72 weeks. For a fuller breakdown of how the two medicines sit side by side, the Wegovy vs Mounjaro comparison on our site goes through the numbers in depth.

The comparison table below summarises the key clinical facts.

Does switching mean losing the progress you've already made?

This is the question our prescribers hear most often from people considering a change. The short answer is: not necessarily, and it depends on why you're switching and how it's managed. If someone moves from tirzepatide to semaglutide at an equivalent stage of their treatment, with appropriate dose bridging, continued progress is possible. What does tend to happen is an adjustment period: the GI profile of semaglutide can feel different, and some people find nausea more prominent in the early weeks on a new agent even if they tolerated tirzepatide well.

The clinical differences between Wegovy and Mounjaro matter here, because the two medicines work differently at receptor level and the body's response to switching is individual. Anyone considering a change for reasons other than clinical recommendation should discuss it with a prescriber before acting. If the switch is driven by cost, our page on the price difference between Mounjaro and Wegovy sets out what to factor in.

Both medicines are prescription-only under UK law, and any switch requires clinical assessment. The NHS's patient information on tirzepatide and its semaglutide equivalent are useful reading alongside your prescriber's guidance. For switches away from tirzepatide for other reasons, changing from Mounjaro to Ozempic is a separate question, Ozempic is licensed for type 2 diabetes, not weight management, which is a clinically important distinction.

Which medicine suits you is a clinical decision our prescribers work through with you, based on your medical history, your current progress, and what matters to you. Check your eligibility with a free consultation and a clinician will review your case the same day.